GlassScriptPhysician profile
Mallory Sousa
NPI 1518795228
$1,489.28
in general payments reported to CMS, 2019-2025
14 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.30 |
| Education | $137.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $377.75 | 2025 | Krystexxa, Otezla, Evenity |
| Abbvie INC. | $235.79 | 2025 | |
| Janssen Biotech, INC. | $221.99 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $160.02 | 2025 | Saphnelo |
| Ucb, INC. | $138.33 | 2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $110.86 | 2025 | Acthar |
| Glaxosmithkline, LLC. | $78.58 | 2025 | Benlysta |
| Organon LLC | $29.71 | 2025 | Renflexis, Hadlima |
| Sobi, INC | $29.09 | 2025 | |
| Ani Pharmaceuticals, INC. | $26.40 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.17 | 2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $20.82 | 2025 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $20.15 | 2025 | Orencia |
| Fresenius Kabi USA, LLC | $13.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Sousa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.